B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors

Growing evidence links the aggressiveness of non-Hodgkin’s lymphoma, especially the activated B cell-like type diffuse large B cell lymphomas (ABC-DLBCLs) to Toll-like receptor 9 (TLR9)/MyD88 and STAT3 transcription factor signaling. Here, we describe a dual-function molecule consisting of a clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xingli, Zhang, Zhuoran, Moreira, Dayson, Su, Yu-Lin, Won, Haejung, Adamus, Tomasz, Dong, Zhenyuan, Liang, Yong, Yin, Hongwei H., Swiderski, Piotr, Pillai, Raju K., Kwak, Larry, Forman, Stephen, Kortylewski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910676/
https://www.ncbi.nlm.nih.gov/pubmed/29433938
http://dx.doi.org/10.1016/j.ymthe.2018.01.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910676/
https://www.ncbi.nlm.nih.gov/pubmed/29433938
http://dx.doi.org/10.1016/j.ymthe.2018.01.007

Ejemplares similares